NO2907506T3 - - Google Patents

Info

Publication number
NO2907506T3
NO2907506T3 NO15161929A NO15161929A NO2907506T3 NO 2907506 T3 NO2907506 T3 NO 2907506T3 NO 15161929 A NO15161929 A NO 15161929A NO 15161929 A NO15161929 A NO 15161929A NO 2907506 T3 NO2907506 T3 NO 2907506T3
Authority
NO
Norway
Application number
NO15161929A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46940567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2907506(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2907506T3 publication Critical patent/NO2907506T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
NO15161929A 2011-07-19 2012-07-13 NO2907506T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2011007675A MX2011007675A (es) 2011-07-19 2011-07-19 Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
EP12766487.8A EP2735306A1 (en) 2011-07-19 2012-07-13 Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans

Publications (1)

Publication Number Publication Date
NO2907506T3 true NO2907506T3 (es) 2018-04-14

Family

ID=46940567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15161929A NO2907506T3 (es) 2011-07-19 2012-07-13

Country Status (34)

Country Link
US (6) US9408836B2 (es)
EP (2) EP2907506B1 (es)
JP (1) JP6034380B2 (es)
KR (2) KR20160074016A (es)
CN (2) CN112386579A (es)
AR (1) AR087205A1 (es)
AU (1) AU2012284627B2 (es)
BR (1) BR112014001297B1 (es)
CA (1) CA2842654C (es)
CL (1) CL2014000131A1 (es)
CO (1) CO6970587A2 (es)
CR (1) CR20140019A (es)
CY (2) CY2200005T2 (es)
DE (1) DE15161929T1 (es)
DK (1) DK2907506T3 (es)
DO (1) DOP2014000010A (es)
EC (1) ECSP14013160A (es)
ES (1) ES2550227T3 (es)
HK (1) HK1208172A1 (es)
HR (1) HRP20180183T1 (es)
HU (1) HUE036511T2 (es)
LT (1) LT2907506T (es)
MX (1) MX2011007675A (es)
NO (1) NO2907506T3 (es)
PE (1) PE20141684A1 (es)
PL (1) PL2907506T3 (es)
PT (1) PT2907506T (es)
RS (1) RS56858B1 (es)
RU (1) RU2682177C2 (es)
SI (1) SI2907506T1 (es)
UA (1) UA114181C2 (es)
UY (1) UY34190A (es)
WO (1) WO2013012307A1 (es)
ZA (1) ZA201400386B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN105997302A (zh) * 2016-07-18 2016-10-12 青岛三帝生物科技有限公司 基于3d打印的防包膜挛缩乳房假体制作方法和乳房假体
MX364040B (es) * 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
KR20180100869A (ko) * 2017-03-02 2018-09-12 영진약품 주식회사 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법
CN107080741A (zh) * 2017-04-28 2017-08-22 北京工业大学 吡非尼酮缓释制剂及制备方法
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
PT3511001T (pt) 2018-01-12 2021-12-29 Tiefenbacher Alfred E Gmbh & Co Kg Formulação de comprimido e cápsula contendo pirfenidona
AU2019261329A1 (en) 2018-04-23 2020-11-12 Inspirmed Corp. Inhalable liposomal sustained release composition for use in treating pulmonary diseases
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
KR102199415B1 (ko) * 2019-02-18 2021-01-06 충북대학교 산학협력단 중합체 및 채널링제를 포함하는 피르페니돈 또는 이의 약학적으로 허용가능한 염의 지연 방출용 정제
JP2023521887A (ja) * 2020-04-14 2023-05-25 エクスカリバー ファーマシューティカルズ，インク． コロナウイルス治療のためのピルフェニドン
WO2021215856A1 (ko) * 2020-04-22 2021-10-28 영진약품 주식회사 안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458048A (en) 1972-12-18 1976-12-08 Affiliated Med Res Pharmaceutical composition
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
JPS51128438A (en) 1975-04-26 1976-11-09 Yamanouchi Pharmaceut Co Ltd An antibacterial drug against fish diseases
SE430609B (sv) 1976-12-21 1983-11-28 Sca Development Ab Sett att ur cellulosaderivat framstella absorberande material
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
SU1719047A1 (ru) * 1989-11-09 1992-03-15 Воронежский инженерно-строительный институт Вибрационный гранул тор
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
ATE212551T1 (de) 1995-12-21 2002-02-15 Pfizer Injizierbare quinolonformulierungen
US5958420A (en) 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
ATE266405T1 (de) 1998-03-17 2004-05-15 Solomon B Margolin Topische antiseptische zusammenstellungen und methoden
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
JP2002526447A (ja) 1998-09-18 2002-08-20 メファ・アクチェンゲゼルシャフト アルキルフェニルピリドンの局所製剤
US6277407B1 (en) * 1998-11-10 2001-08-21 Frederick S. Marius Apparatus and method for tablet fabrication
HUP0104606A3 (en) * 1998-12-18 2003-01-28 Basf Ag A pharmaceutical mixture comprising a profen
IN191090B (es) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
EP1356816B1 (en) * 2001-01-29 2009-12-23 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
WO2004073713A1 (ja) 2003-02-21 2004-09-02 Shionogi & Co., Ltd. ピルフェニドンのゲル剤
US8222299B2 (en) 2003-05-23 2012-07-17 Allium Vitalis Incorporated Organosulfur prodrugs for the prevention and treatment of infectious diseases
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060115503A1 (en) 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20070203202A1 (en) * 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
CA2631497C (en) 2005-12-05 2014-04-22 Bioartificial Gel Technologies Inc. Emulsions of a protein-crosslinked hydrogel matrix and dispersed hydrophobic phase
KR20080106358A (ko) * 2006-03-21 2008-12-04 테바 파마슈티컬 인더스트리즈 리미티드 톨터로딘의 제어 방출 제형
EP2036555B1 (en) * 2006-06-15 2011-11-16 Shanghai Genomics, Inc. The use of pyridone derivatives for preventing and treating radiation injury of lungs
DK2124945T3 (da) * 2006-12-18 2011-08-01 Intermune Inc Fremgangsmåde til at give pirfenidonterapi til en patient
EP2118107A1 (en) 2007-03-02 2009-11-18 Talia Miron Mercaptopurine derivatives as anticancer agents
MX2007006347A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma.
US8383823B2 (en) * 2007-06-20 2013-02-26 Auspex Pharmaceuticals Substituted N-aryl pyridinones
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
CN101244045B (zh) * 2007-12-21 2010-06-30 东华大学 一种零级给药口服控释片剂及其制备方法
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX352342B (es) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos.
MX364040B (es) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Also Published As

Publication number Publication date
RU2014101231A (ru) 2015-08-27
US9962374B2 (en) 2018-05-08
WO2013012307A1 (es) 2013-01-24
KR101632332B1 (ko) 2016-06-22
RU2682177C2 (ru) 2019-03-15
AR087205A1 (es) 2014-02-26
KR20140057248A (ko) 2014-05-12
CY2200005T2 (el) 2016-04-13
ES2550227T3 (es) 2018-03-16
EP2907506A1 (en) 2015-08-19
HRP20180183T1 (hr) 2018-03-09
UY34190A (es) 2013-02-28
SI2907506T1 (en) 2018-03-30
PL2907506T3 (pl) 2018-07-31
DK2907506T3 (en) 2018-02-19
US11052074B2 (en) 2021-07-06
US20210386724A1 (en) 2021-12-16
US20190358213A1 (en) 2019-11-28
JP6034380B2 (ja) 2016-11-30
HUE036511T2 (hu) 2018-07-30
UA114181C2 (uk) 2017-05-10
EP2735306A1 (en) 2014-05-28
US10383862B2 (en) 2019-08-20
AU2012284627A1 (en) 2014-02-27
AU2012284627A8 (en) 2014-04-10
CR20140019A (es) 2014-05-20
EP2907506B1 (en) 2017-11-15
US20140296300A1 (en) 2014-10-02
CA2842654C (en) 2020-09-15
DE15161929T1 (de) 2015-11-12
ZA201400386B (en) 2015-04-29
LT2907506T (lt) 2018-03-12
RS56858B1 (sr) 2018-04-30
ES2550227T1 (es) 2015-11-05
US20160287567A1 (en) 2016-10-06
KR20160074016A (ko) 2016-06-27
BR112014001297B1 (pt) 2021-11-16
HUE15161929T1 (hu) 2016-06-28
DOP2014000010A (es) 2014-06-30
JP2014522861A (ja) 2014-09-08
CO6970587A2 (es) 2014-06-13
US9408836B2 (en) 2016-08-09
CA2842654A1 (en) 2013-01-24
MX2011007675A (es) 2012-07-11
AU2012284627B2 (en) 2017-07-20
ECSP14013160A (es) 2014-02-28
CL2014000131A1 (es) 2014-08-22
HK1208172A1 (en) 2016-02-26
CY1119886T1 (el) 2018-06-27
CN103957892A (zh) 2014-07-30
PT2907506T (pt) 2018-02-22
US20200038386A1 (en) 2020-02-06
PE20141684A1 (es) 2014-11-13
BR112014001297A2 (pt) 2017-02-21
US20180092893A1 (en) 2018-04-05
US11040030B2 (en) 2021-06-22
DK2907506T1 (en) 2015-10-12
CN112386579A (zh) 2021-02-23

Similar Documents

Publication Publication Date Title
BR112013022641A2 (es)
AP3853A (es)
BR112013024383A2 (es)
BR112013026905A2 (es)
BR112013023185A2 (es)
BR112013022995A2 (es)
BR112013017670A2 (es)
BR112013026744A2 (es)
BR112013023927A2 (es)
BR112013024365A2 (es)
BR112013028733A2 (es)
BR112013027121A2 (es)
AP2016009466A0 (es)
BR112013024588A2 (es)
NO2907506T3 (es)
BR112013018949A2 (es)
BR112013026895A2 (es)
BR112013021637A2 (es)
BR112013023266A2 (es)
BR112013025487A2 (es)
BR112013017878A2 (es)
BR112013026861A2 (es)
BR112013032394A2 (es)
BR112013030734A2 (es)
BR112013027112A2 (es)